Is a possible benefit from longer-term docetaxel-based chemotherapy real?

A new paper in JAMA Oncology has suggested that longer docetaxel-based chemotherapy may be associated with longer survival for at least some men being treated for metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …